0001683168-20-003663.txt : 20201103 0001683168-20-003663.hdr.sgml : 20201103 20201103160126 ACCESSION NUMBER: 0001683168-20-003663 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201103 DATE AS OF CHANGE: 20201103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Atomera Inc CENTRAL INDEX KEY: 0001420520 STANDARD INDUSTRIAL CLASSIFICATION: SEMICONDUCTORS & RELATED DEVICES [3674] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37850 FILM NUMBER: 201283455 BUSINESS ADDRESS: STREET 1: 750 UNIVERSITY AVENUE STREET 2: SUITE 280 CITY: LOS GATOS STATE: CA ZIP: 95032 BUSINESS PHONE: 408-442-5248 MAIL ADDRESS: STREET 1: 750 UNIVERSITY AVENUE STREET 2: SUITE 280 CITY: LOS GATOS STATE: CA ZIP: 95032 FORMER COMPANY: FORMER CONFORMED NAME: MEARS TECHNOLOGIES INC DATE OF NAME CHANGE: 20071206 10-Q 1 atomera_i10q-093020.htm FORM 10-Q
0001420520 false --12-31 2020 Q3 0001420520 2020-01-01 2020-09-30 0001420520 2020-10-28 0001420520 2020-09-30 0001420520 2019-12-31 0001420520 2020-07-01 2020-09-30 0001420520 2019-07-01 2019-09-30 0001420520 2019-01-01 2019-09-30 0001420520 us-gaap:CommonStockMember 2019-12-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001420520 us-gaap:RetainedEarningsMember 2019-12-31 0001420520 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001420520 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001420520 2020-01-01 2020-03-31 0001420520 us-gaap:CommonStockMember 2020-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001420520 us-gaap:RetainedEarningsMember 2020-03-31 0001420520 2020-03-31 0001420520 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001420520 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001420520 2020-04-01 2020-06-30 0001420520 us-gaap:CommonStockMember 2020-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001420520 us-gaap:RetainedEarningsMember 2020-06-30 0001420520 2020-06-30 0001420520 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001420520 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001420520 us-gaap:CommonStockMember 2020-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001420520 us-gaap:RetainedEarningsMember 2020-09-30 0001420520 us-gaap:CommonStockMember 2018-12-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001420520 us-gaap:RetainedEarningsMember 2018-12-31 0001420520 2018-12-31 0001420520 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001420520 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001420520 2019-01-01 2019-03-31 0001420520 us-gaap:CommonStockMember 2019-03-31 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001420520 us-gaap:RetainedEarningsMember 2019-03-31 0001420520 2019-03-31 0001420520 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001420520 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001420520 2019-04-01 2019-06-30 0001420520 us-gaap:CommonStockMember 2019-06-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001420520 us-gaap:RetainedEarningsMember 2019-06-30 0001420520 2019-06-30 0001420520 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001420520 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001420520 us-gaap:CommonStockMember 2019-09-30 0001420520 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001420520 us-gaap:RetainedEarningsMember 2019-09-30 0001420520 2019-09-30 0001420520 atom:PublicOfferingMember 2020-01-01 2020-05-15 0001420520 atom:PublicOfferingMember 2020-05-15 0001420520 atom:EquityDistributionAgreementMember atom:CraigHallumCapitalGroupLLCMember 2020-09-02 0001420520 srt:NorthAmericaMember 2020-07-01 2020-09-30 0001420520 srt:NorthAmericaMember 2019-07-01 2019-09-30 0001420520 srt:NorthAmericaMember 2020-01-01 2020-09-30 0001420520 srt:NorthAmericaMember 2019-01-01 2019-09-30 0001420520 srt:EuropeMember 2020-07-01 2020-09-30 0001420520 srt:EuropeMember 2019-07-01 2019-09-30 0001420520 srt:EuropeMember 2020-01-01 2020-09-30 0001420520 srt:EuropeMember 2019-01-01 2019-09-30 0001420520 srt:AsiaPacificMember 2020-07-01 2020-09-30 0001420520 srt:AsiaPacificMember 2019-07-01 2019-09-30 0001420520 srt:AsiaPacificMember 2020-01-01 2020-09-30 0001420520 srt:AsiaPacificMember 2019-01-01 2019-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2020-07-01 2020-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2019-07-01 2019-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-09-30 0001420520 us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-09-30 0001420520 us-gaap:TransferredOverTimeMember 2020-07-01 2020-09-30 0001420520 us-gaap:TransferredOverTimeMember 2019-07-01 2019-09-30 0001420520 us-gaap:TransferredOverTimeMember 2020-01-01 2020-09-30 0001420520 us-gaap:TransferredOverTimeMember 2019-01-01 2019-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001420520 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001420520 atom:UnvestedRestrictedStockMember 2020-07-01 2020-09-30 0001420520 atom:UnvestedRestrictedStockMember 2020-01-01 2020-09-30 0001420520 atom:UnvestedRestrictedStockMember 2019-07-01 2019-09-30 0001420520 atom:UnvestedRestrictedStockMember 2019-01-01 2019-09-30 0001420520 us-gaap:WarrantMember 2020-07-01 2020-09-30 0001420520 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001420520 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001420520 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001420520 stpr:CA 2020-09-30 0001420520 us-gaap:WarrantMember 2019-12-31 0001420520 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001420520 us-gaap:WarrantMember 2020-09-30 0001420520 atom:Plan2017Member 2020-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001420520 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001420520 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001420520 atom:SellingAndMarketingMember 2020-07-01 2020-09-30 0001420520 atom:SellingAndMarketingMember 2019-07-01 2019-09-30 0001420520 atom:SellingAndMarketingMember 2020-01-01 2020-09-30 0001420520 atom:SellingAndMarketingMember 2019-01-01 2019-09-30 0001420520 us-gaap:StockOptionMember 2020-09-30 0001420520 us-gaap:StockOptionMember 2020-01-01 2020-09-30 0001420520 us-gaap:StockOptionMember 2020-07-01 2020-09-30 0001420520 us-gaap:StockOptionMember 2019-01-01 2019-09-30 0001420520 us-gaap:StockOptionMember 2019-12-31 0001420520 us-gaap:RestrictedStockMember 2019-12-31 0001420520 us-gaap:RestrictedStockMember 2020-01-01 2020-09-30 0001420520 us-gaap:RestrictedStockMember 2020-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2020.

 

or

 

¨ Transition Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

For the transition period from __________ to __________

 

Commission file number: 001-37850

 

ATOMERA INCORPORATED

(Exact name of registrant as specified in its charter)

 

Delaware

30-0509586

(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

 

750 University Avenue, Suite 280

Los Gatos, California 95032

(Address, including zip code, of registrant’s principal executive offices)

 

(408) 442-5248

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock: Par value $0.001 ATOM Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ¨ Accelerated Filer x
Non-accelerated filer ¨ Smaller reporting company x
  Emerging Growth Company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

Indicate by checkmark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act: Yes ¨ No x

 

The number of outstanding shares of the Registrant’s Common Stock, par value $.001 per share, as of October 28, 2020 was 21,455,276.

 

 

 

 

 

Atomera Incorporated

 

Index

 

    Page
PART I. Financial Information  
     
Item 1. Financial Statements 3
     
  Condensed Balance Sheets – September 30, 2020 (unaudited) and December 31, 2019 3
     
  Unaudited Condensed Statements of Operations - For the Three and Nine Months Ended September 30, 2020 and 2019 4
     
  Unaudited Condensed Statements of Stockholders’ Equity - For the Three and Nine Months Ended September 30, 2020 and 2019 5
     
  Unaudited Condensed Statements of Cash Flows - For the Nine Months Ended September 30, 2020 and 2019 6
     
  Notes to the Unaudited Condensed Financial Statements 7
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 18
     
Item 4. Controls and Procedures 18
     
PART II. Other Information  
   
Item 1A. Risk Factors 19
     
Item 6. Exhibits 19
     
Signatures 20

 

 

 

 2 

 

 

PART I. Financial Information

 

Item 1. Financial Statements

 

Atomera Incorporated

Condensed Balance Sheets

(in thousands, except per share data)

 

           
   September 30,   December 31, 
   2020   2019 
   (Unaudited)      
ASSETS          
           
Current assets:          
Cash and cash equivalents  $25,297   $14,871 
Prepaid expenses and other current assets   181    132 
Total current assets   25,478    15,003 
           
Property and equipment, net   87    63 
Operating lease right-of-use asset   735    161 
Long-term prepaid rent   450     
Security deposit   13    13 
           
Total assets  $26,763   $15,240 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Accounts payable  $563   $315 
Accrued expenses   234    145 
Accrued payroll related expenses   511    819 
Current operating lease liability   92    152 
Deferred revenue       37 
Total current liabilities   1,400    1,468 
           
Long term operating lease liability   631     
           
Total liabilities   2,031    1,468 
           
Commitments and contingencies (see Note 9)          
           
Stockholders’ equity:          
Preferred stock, $0.001 par value, authorized 2,500 shares; none issued and outstanding at September 30, 2020 and December 31, 2019        
Common stock, $0.001 par value, authorized 47,500 shares; 20,971 and 17,117 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively   21    17 
Additional paid-in capital   170,975    149,017 
Accumulated deficit   (146,264)   (135,262)
Total stockholders’ equity   24,732    13,772 
           
Total liabilities and stockholders’ equity  $26,763   $15,240 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 3 

 

 

Atomera Incorporated

Condensed Statements of Operations

(Unaudited)

(in thousands, except per share data)

 

                     
  

Three Months ended

September 30,

  

Nine Months ended

September 30,

 
   2020   2019   2020   2019 
Revenue  $   $254   $62   $395 
Cost of revenue       (204)   (13)   (224)
Gross margin       50    49    171 
                     
Operating expenses                    
Research and development   2,049    1,746    6,197    5,930 
General and administrative   1,322    1,239    4,247    4,048 
Selling and marketing   208    240    648    712 
Total operating expenses   3,579    3,225    11,092    10,690 
                     
Loss from operations   (3,579)   (3,175)   (11,043)   (10,519)
                     
Other income                    
Interest income   1    89    41    265 
Total other income   1    89    41    265 
                     
Net loss  $(3,578)  $(3,086)  $(11,002)  $(10,254)
Net loss per common share, basic and diluted  $(0.19)  $(0.19)  $(0.61)  $(0.66)
                     
Weighted average number of common shares outstanding, basic and diluted   19,337    16,567    18,028    15,597 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 4 

 

 

Atomera Incorporated

Statements of Stockholders’ Equity

For the Three and Nine Months Ended September 30, 2020 and 2019

(Unaudited)

(in thousands)

 

                          
   Common Stock   Additional
Paid-in
   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Deficit   Equity 
Balance January 1, 2020   17,117   $17   $149,017    (135,262)  $13,772 
Stock-based compensation   420    1    628        629 
Warrant exercise   189        164        164 
Warrant modification           139        139 
Net loss               (3,645)   (3,645)
Balance March 31, 2020   17,726    18    149,948    (138,907)   11,059 
Underwritten public offering of common stock, net of commissions and expenses   2,024    2    9,393        9,395 
Stock option exercise   33        137        137 
Stock-based compensation   43        766        766 
Net loss               (3,779)   (3,779)
Balance June 30, 2020   19,826   $20   $160,244    (142,686)  $17,578 
At-the-market sale of stock, net of commissions and expenses   846    1    8,519        8,520 
Stock option exercise   103        645        645 
Stock-based compensation           829        829 
Warrant Exercise   196        738        738 
Net loss               (3,578)   (3,578)
Balance September 30, 2020   20,971   $21   $170,975    (146,264)  $24,732 

 

 

   Common Stock   Additional
Paid-in
   Accumulated  

Total

Stockholders’

 
   Shares   Amount   Capital   Deficit   Equity 
Balance January 1, 2019   15,034   $15   $139,693   $(121,962)  $17,746 
Stock-based compensation   298        694        694 
Net loss               (3,534)   (3,534)
Balance March 31, 2019   15,332    15    140,387    (125,496)   14,906 
Registered direct offering of common stock, net of commissions and expenses   1,675    2    6,395        6,397 
Stock-based compensation   67        788        788 
Net loss               (3,634)   (3,634)
Balance June 30, 2019   17,074   $17   $147,570   $(129,130)  $18,457 
Stock-based compensation           798        798 
Net loss               (3,086)   (3,086)
Balance September 30, 2019   17,074   $17   $148,368   $(132,216)  $16,169 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 5 

 

 

Atomera Incorporated

Condensed Statements of Cash Flows

(Unaudited)

(in thousands)

 

           
   Nine Months Ended
September 30,
 
   2020   2019 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net Loss  $(11,002)  $(10,254)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   32    33 
Right of use asset amortization   107    99 
Stock-based compensation   2,224    2,280 
Warrant modification expense   139     
Changes in operating assets and liabilities:          
Accounts receivable       (2)
Prepaid expenses and other current assets   (49)   (22)
Long-term prepaid rent   (450)    
Accounts payable   248    (143)
Accrued expenses   89    46 
Accrued payroll expenses   (308)   (362)
Lease liability   (110)   (99)
Deferred revenue   (37)   (55)
Net cash used in operating activities   (9,117)   (8,479)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Acquisition of property and equipment   (56)   (51)
Net cash used in investing activities   (56)   (51)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from underwritten public offering, net of commissions and expenses   9,395     
Proceeds from at-the-market sale of stock, net of commissions and expenses   8,520     
Proceeds from registered direct offering of common stock, net of commissions and expenses       6,397 
Proceeds from exercise of warrants   902     
Proceeds from exercise of stock options   782     
Net cash provided by financing activities   19,599    6,397 
           
Net increase (decrease) in cash and cash equivalents   10,426    (2,133)
           
Cash and cash equivalents at beginning of period   14,871    18,933 
           
Cash and cash equivalents at end of period  $25,297   $16,800 
           
Supplemental information:          
Cash paid for interest  $   $ 
Cash paid for taxes  $   $ 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 6 

 

 

ATOMERA INCORPORATED

NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS

For the Three and Nine Months Ended September 30, 2020

 

1. NATURE OF OPERATIONS

 

Atomera Incorporated (“Atomera” or the “Company”) was incorporated in the state of Delaware in March 2007 under the name MEARS Technologies, Inc. and is engaged in the development, commercialization and licensing of proprietary processes and technologies for the semiconductor industry. On January 12, 2016, the Company changed its name to Atomera Incorporated.

 

The Company is in the development stage, having only recently begun limited revenue-generating activities, and is devoting substantially all of its efforts toward technology research and development and to commercially licensing its technology to designers and manufacturers of integrated circuits. The Company has primarily financed operations through private placements of equity and debt securities, the Company’s Initial Public Offering (the “IPO”) which was consummated on August 10, 2016, and subsequent public offerings of its common stock.

 

On May 15, 2020, the Company closed an underwritten public offering of 2,024,000 shares of common stock at a public offering price of $5.00 per share, resulting in approximately $9.4 million of net proceeds after deducting underwriting commission and other offering expenses.

 

On September 2, 2020, Atomera entered into an Equity Distribution Agreement with Craig-Hallum Capital Group LLC, as agent, under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock, in “at the market” offerings to or through the agent as its sales agent, having an aggregate offering price of up to $25,000,000.

 

2. LIQUIDITY AND MANAGEMENT PLANS

 

At September 30, 2020, the Company had cash and cash equivalents of approximately $25.3 million and working capital of approximately $24.1 million. The Company has generated only limited revenue since inception and has incurred recurring operating losses.

 

Based on the funds it has available as of the date of the filing of this report, the Company believes that it has sufficient capital to fund its current business plans and obligations over at least 12 months from the date that these financial statements have been issued. However, the semiconductor industry is generally slow to adopt new manufacturing process technologies and conducts long testing and qualification processes which have limited the Company’s ability to control, and there can be no assurances of the timing of receipt of meaningful amounts of revenue. In addition, the COVID-19 pandemic has impacted some of the Company’s customer contract negotiations and delayed some engineering work by its customers. Accordingly, the Company may require additional capital, the receipt of which cannot be assured. In the event the Company requires additional capital, there can be no guarantee that funds will be available on commercially reasonable terms, if at all. The Company’s future capital requirements and the adequacy of its available funds will depend on many factors, including the Company’s ability to successfully commercialize its technology in the near term, competing technological and market developments, and the need to enter into collaborations with other companies or acquire technologies to enhance or complement its current offerings. If the Company is unable to secure additional capital, it may be required to curtail its research and development initiatives, change its business strategy and take additional measures to reduce costs in order to conserve its cash.

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Significant accounting policies

 

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 13, 2020 except those noted below under the caption “Adoption of recent accounting standards”.

 

 

 

 7 

 

 

Basis of presentation of unaudited condensed financial information

 

The unaudited condensed financial statements of the Company for the three and nine months ended September 30, 2020 and 2019 have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments) which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2019 was derived from the audited financial statements included in the Company's financial statements as of and for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC on March 13, 2020. These financial statements should be read in conjunction with that report.

 

Adoption of recent accounting standards

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard’s main goal is to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope. The new guidance represents significant changes to accounting for credit losses: (i) full lifetime expected credit losses will be recognized upon initial recognition of an asset in scope; (ii) the current incurred loss impairment model that recognizes losses when a probable threshold is met will be replaced with the expected credit loss impairment method without recognition threshold; and (iii) the estimate of expected credit losses will be based upon historical information, current conditions, and reasonable and supportable forecasts. ASU No. 2016-13 introduces two distinctive credit loss impairment models: (i) current expected credit losses (“CECL”) impairment model (Subtopic 326-20) applicable to financial assets measured at amortized cost; and (ii) available-for-sale debt securities impairment model (Subtopic 326-30). ASU No. 2016-13 is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted this standard on January 1, 2020 and it did not have a material impact on its financial position, results of operations or financial statement disclosure.

 

Recent accounting standards

 

In August 2020, the FASB issued ASU No. 2020-06, Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40).  The new guidance eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation.  This guidance is effective as of January 1, 2022 (Early adoption is permitted effective January 1, 2021).  The Company is currently evaluating the effect the updated standard will have on its financial position, results of operations or financial statement disclosure.

 

 

 

4. REVENUE

 

The Company recognizes revenue when it satisfies a performance obligation by transferring the product or service to the customer, either at a point in time or over time. The Company usually recognizes revenue from integration service agreements at a point in time and integration license agreements over a period of time.

 

Disaggregation of revenue:

 

The following table provides information about disaggregated revenue by primary geographical markets and timing of revenue recognition for the three and nine month periods ended September 30, 2020 and 2019 (in thousands):

 

                    
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2020   2019   2020   2019 
Primary geographic markets                    
North America  $   $50   $62   $50 
Europe       104        187 
Asia Pacific       100        158 
Total  $   $254   $62   $395 
                     
Timing of revenue recognition                    
Products and services transferred at a point in time  $   $222   $62   $240 
Products and services transferred over time       32        155 
Total  $   $254   $62   $395 

 

 

 

 8 

 

 

Unbilled contracts receivable and deferred revenue:

 

Timing of revenue recognition may differ from the timing of invoicing customers. Accounts receivable includes amounts billed and currently due from customers. Unbilled contracts receivable represents unbilled amounts expected to be received from customers in future periods, where the revenue recognized to date exceeds the amount billed, and the right to receive payment is subject to the underlying contractual terms. Unbilled contracts receivable amounts may not exceed their net realizable value and are classified as long-term assets if the payments are expected to be received more than one year from the reporting date.

 

The Company records deferred revenue when revenue will be recognized after invoicing. During the nine months ended September 30, 2020, the Company recognized approximately $37,000 of revenue that was included in deferred revenue as of December 31, 2019.

  

5. BASIC AND DILUTED LOSS PER SHARE

 

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the sum of the weighted average number of shares of common stock outstanding and the dilutive common stock equivalent shares outstanding during the period. The Company’s potentially dilutive common stock equivalent shares, which include incremental common shares issuable upon (i) the exercise of outstanding stock options and warrants and (ii) vesting of restricted stock units and restricted stock awards, are only included in the calculation of diluted net loss per share when their effect is dilutive. Since the Company has had net losses for all periods presented, all potentially dilutive securities are anti-dilutive. Accordingly, basic and diluted net loss per share are equal.

  

The following potential common stock equivalents were not included in the calculation of diluted net loss per common share because the inclusion thereof would be anti-dilutive (in thousands):

 

          
  

Three and Nine Months Ended

September 30,

 
   2020   2019 
Stock Options   3,463    2,935 
Unvested restricted stock   716    480 
Warrants   369    765 
Total   4,548    4,180 

 

 

6. LEASES

 

The Company leases corporate office space in Los Gatos, California. In August 2020, the Company and its landlord amended the lease of this office. This amendment extends the expiration date of the lease from January 2021 to January 2026 and increases the space from 3,396 square feet to 4,101 square feet. Under Accounting Standard Codification (“ASC”) 842, the lease amendment was treated as a separate lease for the new space and a modification of the lease for the original space. An additional right-of-use (“ROU”) asset and lease liability of approximately $681,000 were recorded during the three and nine months ended September 30, 2020. The lease liability is based on the present value of the minimum lease payments, discounted using the Company’s estimated incremental borrowing rate of 5.5%. The lease contains escalating payments on the anniversary of the original commencement which are included in the measurement of the initial lease liability. Additional payments based on a change in the Company’s share of the operating expenses, including property taxes and insurance, are recorded as a period expense when incurred. Lease expense for operating leases consists of the lease payments recognized on a straight-line basis over the lease term. When the additional space is available for use, the Company expects to record an additional ROU asset and corresponding liability of approximately $144,000. This is expected in early 2021.

 

 

 

 9 

 

 

The components of operating lease costs were as follows (in thousands):

 

                    
 

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2020   2019   2020   2019 
Fixed lease costs  $30   $27   $83   $81 
Variable lease costs   9    14    36    40 
Short term lease costs   11    7    28    23 
Total operating lease costs  $50   $48   $147   $144 

 

Future minimum payments under non-cancellable leases as of September 30, 2020 were as follows (in thousands):

 

     
   
For the Year Ended December 31,  Amount
Remaining 2020  $27 
2021   108 
2022   166 
2023   170 
2024 & thereafter   371 
Total future minimum lease payments   842 
Less imputed interest   (119)
Total lease liability  $723 

 

The following table provides supplemental information and non-cash activity related to the Company’s operating leases (in thousands):

 

                    
  

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2020   2019   2020   2019 
Operating cash flow information:                    
Cash paid for amounts included in the measurement of lease liabilities  $41   $40   $123   $120 
Non-cash activity:                    
Right-of-use assets obtained in exchange for the lease obligations  $681   $   $681   $295 

 

 

In October 2019, the Company entered into an agreement to lease a tool for use in the development of the Company’s technology. The lease is for five years at $150,000 per month. The lease commencement date is anticipated to be in November 2020, at which time the Company will account for the lease under ASC 842. A prepayment of $450,000 was made in the nine months ended September 30, 2020, this payment represents the final three payments under the lease and is recorded as a long-term prepaid until the lease commencement, at which time it will be record in accordance with ASC 842.

 

 

 

 10 

 

 

 

7. WARRANTS

 

A summary of warrant activity for the nine months ended September 30, 2020 is as follows (in thousands except per share amounts and contractual term):

 

               
 

Number of

Shares

  

Weighted-

Average

Exercise

Price

  

Weighted-
Average

Remaining

Contractual

Term (In Years)

 
Outstanding at January 1, 2020   765   $5.75      
Exercised   (386)  $2.34      
Expired   (10)  $0.15      
Outstanding at September 30, 2020   369   $9.46    0.8 

  

The warrants outstanding at September 30, 2020 had an intrinsic value of approximately $396,000 based on a per-share stock price of $10.45 as of September 30, 2020.

 

On March 17, 2020, 196,602 warrants with an exercise price of $3.75 were set to expire. Prior to the expiration, the Company entered into an agreement with the warrant holders, whereby it modified the terms of the warrants to extend the expiration date until September 17, 2020 in exchange for the removal of a cashless exercise provision. No other terms were modified. Due to this modification, the Company incurred a modification expense of approximately $139,000 that is included in general and administrative expenses on the Condensed Statement of Operations for the nine months ended September 30, 2020. All of the modified warrants were exercised on August 6, 2020.

  

8. STOCK BASED COMPENSATION

 

In May 2017, the Company’s shareholders approved its 2017 Stock Incentive Plan (“2017 Plan”) after its 2007 Stock Incentive Plan (“2007 Plan”) had expired in March 2017. The 2017 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company’s common stock and for the grant of restricted and unrestricted shares. The 2017 Plan provides for the issuance of 3,750,000 shares of common stock. All of the Company’s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company’s nonemployee directors and other consultants, advisors and other persons who provide services to the Company are eligible to receive incentive awards under the 2017 Plan. Generally, stock options and restricted stock issued under the 2017 Plan vest over a period of one to four years from the date of grant.

 

The following table summarizes the stock-based compensation expense recorded in the Company’s results of operations during the three and nine months ended September 30, 2020 and 2019 for stock options and restricted stock granted under the 2017 Plan and the 2007 Plan (in thousands):

 

                    
 

Three Months Ended

September 30,

  

Nine Months Ended

September 30,

 
   2020   2019   2020   2019 
Research and development  $319   $223   $843   $622 
General and administrative   470    541    1,269    1,557 
Selling and Marketing   40    34    112    101 
   $829   $798   $2,224   $2,280 

 

 

 

 11 

 

 

As September 30, 2020, there was approximately $5.8 million of total unrecognized compensation expense related to unvested share-based compensation arrangements that are expected to vest. This cost is expected to be recognized over a weighted-average period of 2.7 years.

 

The weighted average grant date fair value per share of the options granted under the Company’s 2017 Plan was $7.64 and $2.80 for the three and nine months ended September 30, 2020, respectively. The weighted average grant date fair value per share of the options granted under the Company’s 2017 Plan was $2.50 for the nine months ended September 30, 2019.

 

The following table summarizes stock option activity during the nine months ended September 30, 2020 (in thousands except exercise prices and contractual terms):

 

                    
 

Number of

Shares

  

Weighted-

Average

Exercise

Prices

  

Weighted-
Average

Remaining

Contractual

Term (In Years)

   Intrinsic
Value
 
Outstanding at January 1, 2020   2,935   $   6.36           
Granted   664   $4.20           
Exercised   (136)  $5.76           
Outstanding at September 30, 2020   3,463   $5.97    6.77   $15,677 
Exercisable at September 30, 2020   2,404   $6.62    5.92   $9,358 

 

During the nine months ended September 30, 2020, the Company granted options under the 2017 Plan to purchase approximately 664,000 shares of its common stock to its employees. The fair value of these options was approximately $1.9 million at the time of grant.

 

The Company issues restricted stock to employees, directors and consultants and estimates the fair value based on the closing price on the day of grant. The following table summarizes all restricted stock activity during the nine months ended September 30, 2020 (in thousands except per share data):

 

          
 

Number of

Shares

  

Weighted-

Average

Grant Date
Fair Value

 
Outstanding at January 1, 2020   486   $4.50 
Granted   463   $4.43 
Vested   (233)  $   4.57 
Outstanding non-vested shares at September 30, 2020   716   $4.43 

  

During the nine months ended September 30, 2020, the Company granted approximately 463,000 restricted stock awards under the 2017 Plan to its employees and directors. The fair value of these awards was approximately $2.1 million at the time of grant.

 

 

 

 12 

 

 

 

9. COMMITMENTS AND CONTINGENCIES

  

Litigation, Claims and Assessments

 

The Company may be subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of September 30, 2020, or through the date these financial statements have been issued.

 

10. SUBSEQUENT EVENTS

 

Management has evaluated subsequent events and transactions through the date these financial statements were issued.

 

Between October 1, 2020 and the date of filing this report, the Company issued and sold 484,148 shares of its common stock through the At-The-Market program initiated in September 2020. Net proceeds from the sale of these shares after sales commissions and expenses was approximately $5.0 million.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 13 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of the financial condition and results of operations of Atomera Incorporated should be read in conjunction with our unaudited condensed financial statements and the accompanying notes that appear elsewhere in this filing. Statements in this Quarterly Report on Form 10-Q include forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. Although forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks, uncertainties, and changes in condition, significance, value and effect, including those risk factors set forth under the heading “Risk Factors” within our Prospectus Supplement filed pursuant to Rule 424(b)(5) with the SEC on September 2, 2020 and other documents we subsequently file from time to time with the SEC, such as our Annual Report on Form 10-K filed with the SEC on March 13, 2020, quarterly reports on Form 10-Q and our current reports on Form 8-K. Such risks, uncertainties and changes in condition, significance, value and effect could cause our actual results to differ materially from those expressed herein and in ways not readily foreseeable. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report and are based on information currently and reasonably known to us. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Quarterly Report. Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.

 

Overview

 

We are engaged in the business of developing, commercializing and licensing proprietary processes and technologies for the $450+ billion semiconductor industry. Our lead technology, named Mears Silicon TechnologyTM, or MST®, is a thin film of reengineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the most widely used transistor type in the semiconductor industry. MST is our proprietary and patent-protected performance enhancement technology that we believe addresses a number of key engineering challenges facing the semiconductor industry. We believe that by incorporating MST, transistors can be made smaller, with increased speed, reliability and power efficiency. In addition, since MST is an additive and low-cost technology, we believe it can be deployed on an industrial scale, with machines commonly used in semiconductor manufacturing. We believe that MST can be widely incorporated into the most common types of semiconductor products, including analog, logic, optical and memory integrated circuits.

  

We do not intend to design or manufacture integrated circuits directly. Instead, we develop and license technologies and processes that we believe offer the designers and manufacturers of integrated circuits a low-cost solution to the industry’s need for greater performance and lower power consumption. Our customers and partners include:

 

  · foundries, which manufacture integrated circuits on behalf of fabless manufacturers;

 

  · integrated device manufacturers, or IDMs, which are the fully integrated designers and manufacturers of integrated circuits;

 

  · fabless semiconductor manufacturers, which are designers of integrated circuits that outsource the manufacture of their chips to foundries;

 

  · original equipment manufacturers, or OEMs, that manufacture the epitaxial, or EPI, machines used to deposit semiconductor layers, such as the MST film, onto the silicon wafer; and

 

  · electronic design automation companies, which make tools used throughout the industry to simulate performance of semiconductor products using different materials, design structures and process technologies.

  

 

 

 14 

 

 

Our commercialization strategy is to generate revenue through licensing arrangements whereby foundries, IDMs and fabless semiconductor manufacturers pay us a license fee for their right to use MST technology in the manufacture of silicon wafers as well as a royalty for each silicon wafer or device that incorporates our MST technology. To date we have generated revenue from (i) licensing agreements with two IDMs and one fabless manufacturer and (ii) engineering services provided to foundries, IDMs and fabless companies.

 

We were organized as a Delaware limited liability company under the name Nanovis LLC on November 26, 2001. On March 13, 2007, we converted to a Delaware corporation under the name Mears Technologies, Inc. On January 12, 2016, we changed our name to Atomera Incorporated.

 

On August 10, 2016, we closed our initial public offering of 3,680,000 shares of common stock at a public offering price of $7.50 per share. We received approximately $24.7 million in net proceeds after deducting underwriting discounts and commission and other offering expenses.

 

On October 15, 2018, we closed an underwritten public offering of 2,625,000 shares of common stock at a public offering price of $4.75 per share, resulting in approximately $11.4 million of net proceeds to us after deducting underwriting discounts and commission and other offering expenses.

 

On May 30, 2019, we closed a registered direct offering of 1,675,000 shares of common stock at a price of $4.00 per share, resulting in approximately $6.4 million of net proceeds to us after deducting placement agent fees and other offering expenses.

 

On May 15, 2020, we closed an underwritten public offering of 2,024,000 shares of common stock at a public offering price of $5.00 per share, resulting in approximately $9.4 million of net proceeds to us after deducting underwriting commission and other offering expenses.

 

On September 2, 2020, we entered into an Equity Distribution Agreement with Craig-Hallum Capital Group LLC, as agent, under which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $25.0 million in an “at-the-market” or ATM offering, to or through the agent. As of September 30, 2020, 845,730 shares have been sold at an average price of approximately $10.48 million, resulting in approximately $8.5 million of net proceeds to us after deducting commissions and other offering expenses. Between October 1, 2020 and the date of tiling this report, we sold an additional 484,148 shares of our common stock at average price of $10.62 resulting in net proceeds of approximately $5.0 million

   

Results of Operations

 

Revenues. To date, we have only generated limited revenue from customer engagements for integration engineering services and integration license agreements. In the future, we expect to collect increased fees from license agreements and royalties from customer sales of products that incorporate our MST technology, subject to our ability to enter into manufacturing and distribution license agreements with our current and future licensees. Our integration services consist of depositing our MST film on semiconductor wafers, delivering such wafers to customers to finalize building devices, and performing tests for customers evaluating MST. The integration license agreements we have entered into to date grant the licensees the right to build products that integrate our MST technology deposited by us onto their semiconductor wafers, but the agreements do not grant the licensees the rights to manufacture on their site or to sell products incorporating MST. For revenue recognition purposes, we have determined that the grant of rights in integration licenses is not distinct from the delivery of integration services, and therefore revenue from both integration licenses and integration services is recognized as the services are provided to the customer. In general, this is proportionate to the delivery of MST processed wafers to the customer, but if the agreements do not specify a time and quantity of wafer delivery, we will record revenue over the period of time of which we anticipate delivering an estimated quantity of wafers.

 

 

 

 15 

 

 

Revenue for the three months ended September 30, 2020 and 2019 was approximately $0 and $254,000, respectively. Revenue for the nine months ended September 30, 2019 was approximately $62,000 and $395,000, respectively. Revenue in all periods was generated from integration license agreements and integration engineering services.

 

Cost of Revenue. Cost of revenue consists of costs of materials, as well as direct compensation and expenses incurred to provide integration engineering services. Cost of revenue was approximately $0 and $204,000 for the three months ended September 30, 2020 and 2019, respectively. Cost of revenue was approximately $13,000 and $224,000 for the nine months ended September 30, 2020 and 2019, respectively. We anticipate that our cost of revenue will vary substantially depending on the mix of integration license and integration engineering services and the nature of products and/or services delivered in each customer engagement.

 

Operating Expenses. Operating expenses consist of research and development, general and administrative, and selling and marketing expenses. For the three months ended September 30, 2020 and 2019 our operating expenses totaled approximately $3.6 million and $3.2 million, respectively. For the nine months ended September 30, 2020 and 2019 our operating expenses totaled approximately $11.1 million and $10.7 million, respectively.

  

Research and development expense. To date, our operations have focused on the research, development, patent protection, and commercialization of our processes and technologies related to MST. Our research and development costs primarily consist of payroll and benefit costs for our engineering staff and costs of outsourced fabrication and metrology of semiconductor wafers incorporating our MST technology.

 

For the three months ended September 30, 2020 and 2019, we incurred approximately $2.0 million and $1.7 million, respectively, of research and development expense, an increase of approximately $303,000 or 17%. The increase in research and development expense is primarily due to additional headcount and an increase in outsourced research and development costs.

 

For the nine months ended September 30, 2020 and 2019, we incurred approximately $6.2 million and $5.9 million, respectively, of research and development expense, an increase of approximately $267,000 or 5%. The increase in research and development expense is primarily due to additional headcount offset by a decrease in outsourced research and development costs.

 

General and administrative expense. General and administrative expenses consist primarily of payroll and benefit costs for administrative personnel, office-related costs and professional fees. General and administrative costs for the three months ended September 30, 2020 and 2019 were approximately $1.3 million and $1.2 million, respectively, representing an increase of approximately $83,000 or 7%. The increase in general and administrative expenses is primarily the due the increase in legal expenses related to increasing and maintaining our patent portfolio.

 

General and administrative costs for the nine months ended September 30, 2020 and 2019 were approximately $4.2 million and $4.0 million, respectively, representing an increase of approximately $199,000 or 5%. The increase in costs was primarily due to an increase of approximately $384,000 in professional fees primarily for patent expenses, director fees related to the addition of a new independent board member and an approximately $139,000 expense resulting from the modification of expiring warrants (see note 7 to our condensed financial statements included elsewhere in this report). These increases were offset by a decrease in stock-based compensation expense of approximately $288,000.

 

Selling and marketing expense. Selling and marketing expenses consist primarily of salary and benefits for our sales and marketing personnel. Selling and marketing expenses for the three months ended September 30, 2020 and 2019 were approximately $208,000 and $240,000, respectively, representing a decrease of approximately $32,000, or 13%. The decrease in costs is primarily related to a lower bonus accrual.

 

 

 

 16 

 

 

Selling and marketing expenses for the nine months ended September 30, 2020 and 2019 were approximately $648,000 and $712,000, respectively, representing a decrease of approximately $64,000, or 9%. The decrease in costs is primarily related to a reduction of approximately $22,000 in payroll related expenses and a decline of $47,000 in travel expenses.

 

Interest income. Interest income for the three months ended September 30, 2020 and 2019 was approximately $1,000 and $89,000, respectively. Interest income for the nine months ended September 30, 2020 and 2019 was approximately $41,000 and $265,000, respectively. Interest income for each period related to interest earned on our cash and cash equivalents and decreased as our average cash balances declined and interest rates continued to fall during 2020. While we finished the quarter with a higher cash balance, most of the cash was received at the end of the period.

 

Cash Flows from Operating, Investing and Financing Activities

  

Net cash used in operating activities of approximately $9.1 million for the nine months ended September 30, 2020 resulted primarily from our net loss of approximately $11.0 million adjusted by approximately $2.2 million in stock-based compensation expense offset by increase of approximately $499,000 in prepaids and other assets.

 

Net cash used in operating activities of approximately $8.5 million for the nine months ended September 30, 2019 resulted primarily from our net loss of approximately $10.3 million adjusted by approximately $2.3 million for stock-based compensation expense and a decrease in liabilities of approximately $514,000.

 

Net cash used in investing activities of approximately $56,000 for the nine months ended September 30, 2020 and approximately $51,000 for nine months ended September 30, 2019 consisted of the purchase of computers and lab equipment.

 

Net cash provided by financing activities of approximately $19.6 million for the nine months ended September 30, 2020 was primarily related to the net proceeds from our underwritten public offering in May 2020, proceeds from our ATM program in September 2020 and the exercise of approximately 386,000 warrants and approximately 136,000 stock options during this nine-month period.

 

Net cash provided by financing activities of approximately $6.4 million for the nine months ended September 30, 2019 related to the net proceeds from our registered direct offering of common stock in May 2019.

 

Liquidity and Capital Resources

 

As of September 30, 2020, we had cash and cash equivalents of approximately $25.3 million and working capital of approximately $24.1 million. For the nine months ended September 30, 2020, we had a net loss of approximately $11.0 million and used approximately $9.1 million of cash and cash equivalents in operations. Since inception, we have incurred recurring operating losses.

 

As of the date of this report, we believe that our available working capital is sufficient to fund our working capital requirements for at least the next 12 months following the date of the filing of this report. However, the semiconductor industry is generally slow to adopt new manufacturing process technologies and conducts long testing and qualification processes which we have limited ability to control, and there can be no assurance of the timing of our receipt of meaningful amounts of revenue. In addition, the ongoing COVID-19 pandemic has impacted some customer contract negotiations and delayed engineering work by some of our customers. Accordingly, the economic uncertainty caused by the pandemic may negatively impact our ability to generate revenue.

 

 

 

 17 

 

  

Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability, in the near term, to successfully commercialize our MST technology, competing technological and market developments; and the need to enter into collaborations with other companies or acquire technologies to enhance or complement our current offerings. If we are not able to generate sufficient revenue from license fees and royalties in a timeframe that satisfies our cash needs, we will need to raise more capital. In the event we require additional capital, we will endeavor to acquire additional funds through various financing sources, including follow-on equity offerings, debt financing and joint ventures with industry partners. In addition, we will consider alternatives to our current business plan that may enable to us to achieve revenue-producing operations and meaningful commercial success with a smaller amount of capital. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives, change our business strategy and take additional measures to reduce costs in order to conserve cash.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements or issued guarantees to third parties.

  

Recent Accounting Standards

 

We are required to adopt certain new accounting standards, see note 3 to the condensed financial statements included in Item 1 of this Form 10-Q.

 

Critical Accounting Policies

 

There have been no changes to our critical accounting policies from those included in our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020.

  

Item 3. Quantitative and Qualitative Disclosure about Market Risk.

 

Not applicable.

  

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our chief executive officer and principal financial and accounting officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934. Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of September 30, 2020.

 

Changes in Internal Control over Financial Reporting

 

There have not been any changes to our internal controls over financial reporting (as defined by Rule 13a-15(f) and 15(d)-15(f) under the Exchange Act) during the three-month period ended September 30, 2020 that have material affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

 

 

 

 

 

 

 

 18 

 

 

PART II. Other Information

 

Item 1A. Risk Factors

 

The primary risk factors affecting our business have not changed materially from the risk factors set forth in our Prospectus Supplement filed with the SEC on September 2, 2020 or our Annual Report on Form 10-K for the year ended December 31, 2019.

 

Item 6. Exhibits

 

The following is a list of exhibits filed as part of this Report on Form 10-Q:

 

Exhibit

No.

  Description   Method of Filing
31.1   Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   Filed electronically herewith
         
31.2   Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   Filed electronically herewith
         
32.1   Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350).   Filed electronically herewith
         
10.1   Equity Distribution Agreement dated as of September 2, 2020 between the Company and Craig-Hallum Capital Group LLC   Incorporated by reference from the Company’s Current Report on Form 8-K filed on September 2, 2020
         
101.INS   XBRL Instance Document   Filed electronically herewith  
         
101.SCH   XBRL Taxonomy Extension Schema Document   Filed electronically herewith
         
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document   Filed electronically herewith
         
101.LAB   XBRL Taxonomy Extension Label Linkbase Document   Filed electronically herewith
         
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document     Filed electronically herewith
         
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document     Filed electronically herewith

 

 

 

 

 

 

 

 19 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and the on the date indicated.

 

  ATOMERA INCORPORATED.  
     
Date: November 3, 2020 By: /s/ Scott A. Bibaud  
    Scott A. Bibaud
Chief Executive Officer,
 
    (Principal Executive Officer)  
    and Director  
       
       
Date: November 3, 2020 By: /s/ Francis B. Laurencio  
    Francis B. Laurencio  
    Chief Financial Officer  
    (Principal Financial and  
    Accounting Officer)  

 

 

 

 

 

 

 

 

 

 

 

 

 

 20 

EX-31.1 2 atomera_10q-ex3101.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATIONS

 

I, Scott A. Bibaud, certify that:

 

(1) I have reviewed this Form 10-Q of Atomera Incorporated (the “Company”);
   
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
   
(4) The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and15d- 15(f)) for the company and have:
     
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; And
     
(5) The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
     
  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

  ATOMERA INCORPORATED
     
     
Date: November 3, 2020 By: /s/ Scott A. Bibaud
    Scott A. Bibaud, Chief Executive Officer

 

 

 

EX-31.2 3 atomera_10q-ex3102.htm CERTIFICATION

Exhibit 31.2

 

CERTIFICATIONS

 

I, Francis B. Laurencio, certify that:

 

(1) I have reviewed this Form 10-Q of Atomera Incorporated (the “Company”);
   
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;
   
(4) The Company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and15d- 15(f)) for the company and have:
     
  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and
     
  (d) disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; And
     
(5) The Company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):
     
  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and
     
  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

  ATOMERA INCORPORATED
     
     
Date: November 3, 2020 By: /s/ Francis B. Laurencio
   

Francis B. Laurencio, Chief Financial Officer

(Principal Financial Officer)

 

EX-32.1 4 atomera_10q-ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 18

U.S.C. 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Atomera Incorporated (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott A. Bibaud, the Chief Executive Officer, and Francis B. Laurencio, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

  1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

By: /s/ Scott A. Bibaud   Dated: November 3, 2020
  Scott A. Bibaud    
  Title: President and Chief Executive Officer    
       
By: /s/ Francis B. Laurencio   Dated: November 3, 2020
  Francis B. Laurencio    
  Title:  Chief Financial Officer    

 

This certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.

 

EX-101.SCH 5 atom-20200930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - LIQUIDITY AND MANAGEMENT PLANS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - BASIC AND DILUTED LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - LIQUIDITY AND MANAGEMENT PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - REVENUE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - BASIC AND DILUTED LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - LEASES (Details - Lease costs) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - LEASES (Details - Minimum lease payments) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - LEASES (Details - Cash flow effect) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - WARRANTS (Details - Warrant activity) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCK BASED COMPENSATION (Details - Compensation Expense) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCK BASED COMPENSATION (Details - Stock Option Activity) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCK BASED COMPENSATION (Details - Restricted stock) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCK BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 atom-20200930_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 atom-20200930_def.xml XBRL DEFINITION FILE EX-101.LAB 8 atom-20200930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Sale of Stock [Axis] Public Offering [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Equity Distribution Agreement [Member] Legal Entity [Axis] Craig Hallum Capital Group L L C [Member] Geographical [Axis] North America [Member] Europe [Member] Asia Pacific [Member] Timing of Transfer of Good or Service [Axis] Transferred at Point in Time [Member] Transferred over Time [Member] Antidilutive Securities [Axis] Share-based Payment Arrangement, Option [Member] Unvested Restricted Stock [Member] Warrant [Member] CALIFORNIA Award Type [Axis] Plan Name [Axis] 2017 Plan [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Selling and Marketing [Member] Equity Option [Member] Restricted Stock [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Prepaid expenses and other current assets Total current assets Property and equipment, net Operating lease right-of-use asset Long-term prepaid rent Security deposit Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Accrued payroll related expenses Current operating lease liability Deferred revenue Total current liabilities Long term operating lease liability Total liabilities Commitments and contingencies (see Note 9) Stockholders’ equity: Preferred stock, $0.001 par value, authorized 2,500 shares; none issued and outstanding at September 30, 2020 and December 31, 2019 Common stock, $0.001 par value, authorized 47,500 shares; 20,971 and 17,117 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value (in dollars per share) Preferred stock, authorized Preferred stock, issued Preferred stock, outstanding Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, oustanding Income Statement [Abstract] Revenue Cost of revenue Gross margin Operating expenses Research and development General and administrative Selling and marketing Total operating expenses Loss from operations Other income Interest income Total other income Net loss Net loss per common share, basic and diluted Weighted average number of common shares outstanding, basic and diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Registered direct offering of common stock, net of commissions and expenses Registered direct offering of common stock, net of commissions and expenses, shares Stock-based compensation Stock-based compensation, shares Warrant Exercise Warrant exercise, shares Warrant modification Net loss Underwritten public offering of common stock, net of commissions and expenses Underwritten public offering of common stock, net of commissions and expenses, shares Stock option exercise Stock option exercise, shares At-the-market sale of stock, net of commissions and expenses At-the-market sale of stock, net of commissions and expenses, shares Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Right of use asset amortization Stock-based compensation Warrant modification expense Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Long-term prepaid rent Accounts payable Accrued expenses Accrued payroll expenses Lease liability Deferred revenue Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Acquisition of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from underwritten public offering, net of commissions and expenses Proceeds from at-the-market sale of stock, net of commissions and expenses Proceeds from registered direct offering of common stock, net of commissions and expenses Proceeds from exercise of warrants Proceeds from exercise of stock options Net cash provided by financing activities Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental information: Cash paid for interest Cash paid for taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS LIQUIDITY AND MANAGEMENT PLANS Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Revenue from Contract with Customer [Abstract] REVENUE Earnings Per Share [Abstract] BASIC AND DILUTED LOSS PER SHARE Leases LEASES Equity [Abstract] WARRANTS Share-based Payment Arrangement [Abstract] STOCK BASED COMPENSATION Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of presentation of unaudited condensed financial information Adoption of recent accounting standards Information about disaggregated revenue and timing of revenue Schedule of anti dilutive shares Components of lease costs Schedule of future minimum lease payments Supplemental non-cash activity related to operating leases Schedule of warrant activity Schedule of stock-based compensation expense Schedule of stock option activity Schedule of restricted stock option activity Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Stock Issued During Period, Shares, New Issues Sale of Stock, Price Per Share Proceeds from Issuance of Common Stock Maximum offering price Working capital Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenue recognized that was previously included in deferred revenue Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potential common stock equivalents Leases [Abstract] Fixed lease costs Variable lease costs Short term lease costs Total operating lease costs Remaining 2020 2021 2022 2023 2024 & thereafter Total future minimum lease payments Less imputed interest Total lease liability Operating cash flow information: Cash paid for amounts included in the measurement of lease liabilities Non-cash activity: Right-of-use assets obtained in exchange for the lease obligations Lessee, Lease, Description [Line Items] Operating lease liability Incremental borrowing rate Additional right-of-use assets Additional lease liability Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Warrants outstanding, beginning balance Weighted-average exercise price, warrants outstanding, beginning balance Warrants exercised Weighted-average exercise price, warrants exercised Warrant expired Weighted-average exercise price, warrants expired Warrants outstanding, ending balance Weighted-average exercise price, warrants outstanding, ending balance Weighted-average remaining contractual term Warrant intrinsic value Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Allocated stock-based compensation Options outstanding, beginning balance Weighted average exercise price, options outstanding beginning balance Options granted Weighted average exercise price, options granted Options exercised Weighted average exercise price, options exercised Options outstanding, ending balance Weighted average exercise price, options outstanding, ending balance Weighted average remaining contractual term, options outstanding Intrinsic value, options outstanding ending balance Options exercisable Weighted average exercise price, options exercisable Weighted average remaining contractual term, options exercisable Intrinsic value, options exercisable Restricted stock outstanding, beginning balance Restricted stock outstanding, beginning balance Restricted stock granted Restricted stock granted Restricted stock vested Restricted stock vested Restricted stock outstanding, ending balance Restricted stock outstanding, ending balance Shares authorized for issuance Unrecognized compensation expense Unrecognized compensation weighted average period Weighted average grant date fair value per share Fair value of options granted Fair value of restricted stock granted Working capital Weighted-average exercise price, warrants exercised Weighted-average exercise price, warrants expired Selling And Marketing Member Amount paid for fair value of options granted. Fair value of restricted stock granted Amount necessary to reduce net minimum lease payments to present value for operating leases. Assets, Current Assets Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Cost of Goods and Services Sold Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Prepaid Rent Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Lease, Cost Operating Leases, Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsInterestIncludedInPayments Class of Warrant or Right, Outstanding Class of Warrant or Right, Exercise Price of Warrants or Rights Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period EX-101.PRE 9 atom-20200930_pre.xml XBRL PRESENTATION FILE